Your Oncology CRO Partner

Guiding Oncology Therapies from Early Detection of Response to Approval

Partner with a collaborative oncology CRO 
that believes in your research as much as you do.

Get Started

Podcast

Podcast|December 17, 2025

Steve Gately Joins Bourne Partners for a Deep Dive on the Future of Oncology CROs

Listen Now

Press Release

News|December 11, 2025

TD2 Oncology Expands Flow Cytometry Expertise to Advance In Vivo CAR T Therapies for Autoimmune and Oncology Development

Read More

Webinar

Webinar|January 26, 2026

FIH Clinical Trial Planning for Radiopharmaceuticals: From IND to Patient Dosing

Register Now

Case Study

Article|November 20, 2025

Preparing Clinical Sites for Radiopharmaceutical Trials: A Comprehensive Guide

Read More

Press Release

News|July 29, 2025

TD2 Oncology and Curadh Enter Strategic Collaboration to Advance Radiopharmaceutical Clinical Trials

Read More

OUR CAPABILITIES

We Have You Covered Throughout Every Phase

icon-pill-bottle

Clinical Trial Services

We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.
Learn More
icon-mouse-3

Preclinical

In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.
Learn More
icon-clipboard

Regulatory Support

Your therapy’s journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.
Learn More
icon-pk-adme2

Flow Cytometry

Gain valuable insights into your drug’s therapeutic effects with TD2’s high-throughput flow cytometry platform, designed to support diverse assays and cell types. Our advanced immunophenotyping capabilities help uncover your drug’s mechanism of action and pharmacodynamics.
Learn More
WHAT WE DO

The TD2 Oncology Ecosystem

At TD2, we are revolutionizing oncology research through an integrated ecosystem that brings together preclinical services, advanced flow cytometry, robust regulatory support, an extensive site network, and comprehensive clinical trial services. Our mission is to accelerate the development of innovative cancer therapies.

Learn more
ABOUT TD2

Accelerating Cancer Drug Development

Since 2003, TD2 has made an impact beyond what is expected of a traditional oncology CRO. Not only do we work with hundreds of biotech and pharma companies to rapidly move new therapy discoveries to market through proactive problem solving and strategic collaboration, but we are also drug development innovators. The breadth of our services gives us the unique ability to translate scientific hypotheses generated in a lab setting into patient responses in the clinic. Our results consistently outpace our competition due to a dynamic, flexible and highly specialized team that is laser-focused on oncology.

meet our team

CONTACT US

Work with a team who believes in your research as much as you do.

Are you ready to move your cancer therapy to market? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.

Learn more

Latest blog Posts